An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant. (PubMed, Clin Infect Dis) - Dec 1, 2025 - "Positive QuantiFERON-CMV results increased after letermovir prophylaxis completion. Predictive utility of the QuantiFERON-CMV assay may be limited in the HCT setting."
Journal • P3 data • Cytomegalovirus Infection • Infectious Disease • Transplantation
|
|
Barbara Haber; Christopher L Gilbert; Cyrus Badshah; Eleni Tholouli; Ella J Ariza-Heredia; Genovefa A Papanicolaou; Michele I Morris; Natalya Broyde; Patrizia Chiusolo; Sanjeet S Dadwal
|